Sunday, November 1, 2026

Intel Stock Over 28% Up In The Last 21 Sessions

Intel Stock Over 28% Up In The Last 21 Sessions

(VIANEWS) - Shares of Intel (NASDAQ: INTC) jumped by a staggering 28.24% in 21 sessions from $25.99 at 2023-03-06, to $33.33 at 11:50 EST on Tuesday, after five successive sessions in a row of gains. NASDAQ is falling 0.39% to $12,141.52, following the last session's downward trend.

Intel's last close was $32.89, 33.19% below its 52-week high of $49.23.

About Intel

Intel Corporation designs, develops, manufactures, markets, and sells computing and related products worldwide. It operates through Client Computing Group, Data Center and AI, Network and Edge, Mobileye, Accelerated Computing Systems and Graphics, Intel Foundry Services, and Other segments. The company offers platform products, such as central processing units and chipsets, and system-on-chip and multichip packages; and accelerators, boards and systems, connectivity products, and memory and storage products. It also provides high-performance compute solutions for targeted verticals and embedded applications for retail, industrial, and healthcare markets; and solutions for assisted and autonomous driving comprising compute platforms, computer vision and machine learning-based sensing, mapping and localization, driving policy, and active sensors. In addition, the company offers workload-optimized platforms and related products for cloud service providers, enterprise and government, and communications service providers. It serves original equipment manufacturers, original design manufacturers, cloud service providers, and other equipment manufacturers. The company was incorporated in 1968 and is headquartered in Santa Clara, California.

Earnings Per Share

As for profitability, Intel has a trailing twelve months EPS of $4.46.

PE Ratio

Intel has a trailing twelve months price to earnings ratio of 7.48. Meaning, the purchaser of the share is investing $7.48 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.07%.

Growth Estimates Quarters

The company's growth estimates for the present quarter and the next is a negative 117.2% and a negative 93.1%, respectively.

Sales Growth

Intel's sales growth is negative 39.7% for the present quarter and negative 23% for the next.

Yearly Top and Bottom Value

Intel's stock is valued at $33.33 at 11:50 EST, way under its 52-week high of $49.23 and way above its 52-week low of $24.59.

Revenue Growth

Year-on-year quarterly revenue growth declined by 31.6%, now sitting on 63.05B for the twelve trailing months.

More news about Intel (INTC).

In this story · Knowledge Files

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com